Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) (EspacECU)

Eculizumab is an anti-C5 monoclonal antibody approved for rare diseases including atypical haemolytic-uraemic syndrome. The maintenance phase dosing regimen is identical for all adult patients

  • 0 views
  • 16 Mar, 2022
  • 14 locations
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder

eculizumab
immunosuppressive therapy
immunosuppressive agents
human chorionic gonadotropin
aquaporin 4
  • 18 views
  • 05 May, 2022
  • 17 locations
A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors. (COMMODORE 1)

A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll

high sensitivity
complement inhibitor
neisseria meningitidis
paroxysmal nocturnal hemoglobinuria
flow cytometry
  • 0 views
  • 13 Oct, 2022
  • 103 locations
Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

treated with eculizumab who still experience anemia and reticulocytosis, or patients currently treated with ALXN2040 (danicopan) as monotherapy. After signing consent, participants will have periodic

platelet count
complement inhibitor
anemia
neutrophil count
paroxysmal nocturnal hemoglobinuria
  • 41 views
  • 07 Oct, 2022
  • 8 locations
The Use of Eculizumab in HELLP Syndrome

) benefit from a medication called eculizumab (ECU). This drug blocks a part of the immune system called complement. By blocking this part of the immune system, eculizumab may stop or reverse the

  • 0 views
  • 22 Jun, 2021
  • 1 location
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)

treatment, in patients with PNH who switch from eculizumab or ravulizumab therapy versus patients who continue their eculizumab or ravulizumab therapy The secondary objectives of the study are to

eculizumab
hemolysis
flow cytometry
lactate dehydrogenase
ravulizumab
  • 0 views
  • 25 Mar, 2022
Therapeutic Orientation Test in Thrombotic Microangiopathy (TOTEM)

Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody (Eculizumab) wich

  • 0 views
  • 22 Mar, 2022
  • 1 location
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

  • 203 views
  • 30 Jan, 2022
  • 65 locations
Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

This study will collect clinical response data on participants who were already treated with eculizumab for at least 26 weeks and who started ravulizumab treatment as a specific therapeutic

eculizumab
hemolysis
neisseria meningitidis
ravulizumab
flow cytometry
  • 0 views
  • 04 Oct, 2022
  • 6 locations
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

The aim of this trial is to collect data and provide a better understanding of the long-term outcome of imlifidase treatment on active or chronic active antibody-mediated rejection (AMR) in kidney transplant recipients. This is done by collecting data during an extended follow-up period of 3 years of clinical study …

  • 0 views
  • 27 May, 2022
  • 6 locations